TB Alliance’s ZeNix trial in South Africa and Eastern Europe sought to optimize the 6-month treatment regimen with reduced exposure
TOKYO and NEW YORK (March 31, 2021)—Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and
March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal
PRETORIA (24 March 2021)—TB Alliance welcomes today’s announcement of the early closing of randomization into the TB-PRACTECAL study. TB-PRACTECAL is a
NEW YORK (March 23, 2021) – Interested researchers are invited to apply to access the MARK-TB (Markedly Accelerating Research with
Throughout TB Alliance’s history, it has expanded its pursuit and advocacy for various types of TB research, as it identifies
NEW YORK (March 18, 2021)—TB Alliance and GSK have agreed to extend their longstanding collaboration to discover new compounds that
WALTHAM, Mass., February 1, 2021 – ZebiAI, Inc., a biotech company focused on improving human health by powering machine learning (ML) to
NEW YORK (December 15, 2020)—TB Alliance announced that on December 1, 2020 the first dose was administered to a patient
Guilford, Conn., June 2, 2020, InveniAI® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning
